Leeds, UK -- (SBWIRE) -- 07/22/2019 -- The global hemophehilia treatment market is forecasted to value over US$ 15 billion by the end of 2026 and grow at a CAGR of over 5% during the forecast period of 2019-2026.

Hemophilia is a hereditary genetic disorder where the body's coagulation control or blood clotting ability is impaired. Basically, due to lack of sufficient amount of blood-clotting proteins or clotting factors, your blood is unable to clot normally. The inherited hemophilia is generally found in men as it is passed to them by the X chromosome of their mother. Hemophilia occurs in three forms – hemophilia A, hemophilia B and hemophilia C. The most commonly formed is the hemophilia A which is due to lack of factor VIII. Hemophilia B occurs due to lack of factor IX and hemophilia C occurs due to lack of factor XI. Utilization of innovative techniques and technological advancements are the driving force for the growth of the global market. According to World Federation of Hemophilia (WFH), hemophilia A affects 1 in 5000 males that take birth. It is estimated that around 75% of the global hemophilia patient pool has no proper access to treatment. Therefore, in order to provide consistent treatment for patients, agencies like Hemophilia Association of America (HAA) have pursued key market players for the introduction of co-pay assistance initiatives. For instance, CSL Behring made a donation of 1.5 million units of their anti-hemophilic agents on world hemophilia day which is on April 17. At present, there is no cure present for hemophilia A and treatments are primarily conducted to manage the disease. Due to the lack of provision of medical needs and monopolistic opportunities for manufacturers, there is a huge demand for effective hemophilia management. Also, due to the presence of limited amount of therapies and regulatory authorities facing a huge task on the treatment of these disorders, the research and development also get a boost so that they can identify curative agents which in turn will help to accelerate growth during the forecast period.

Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=196&page=requestsample

Insights on Hemophilia Treatment Market:
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Rest of the world
North America is expected to be a major shareholder of the global market due to high awareness and supportive regulatory policies. European region follows North America and is expected to have a significant share during the forecast period. Asia Pacific regions are expected to experience a rapid market growth rate due to changing healthcare policies and increasing awareness. Latin America and the rest of the world are both expected to possess a small fraction of the global market due to lack of awareness.

By Type of Product
- Recombinant clotting factors concentrate
- Plasma derived factor concentrates

By Type of Disease
- Hemophilia A
- Hemophilia B
- Hemophilia C
Hemophilia A treatments are expected to grow at a higher rate in the market as compared to hemophilia B and hemophilia C during the forecast period due to the prevalence of the disease throughout the world.

Purchase a Copy of this Premium Research Report & Ask for Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=196&page=askfordiscount

By End User
- Hospital
- Clinic
- Others
The hospital segment is expected to get a boost in the market growth during the forecast period as more and more multi-speciality hospitals are being built which provide hemophilia treatments and has an infrastructural advantage over the clinics and this trend will be observed in the North American and European regions due to the high spending capacity of the general population. On the other hand, clinic treatments will obtain a rapid growth rate in emerging economies due to lesser treatment cost as compared to hospitals.

Competitive Landscape:
- Baxter International Inc.
- Bayer AG
- Pfizer
- Biogen Idec Inc.
Baxter International Inc. has obtained approval for Obizur, which is a recombinant concentrate for treating hemophilia A which will help them get some market share during the forecast period because it is the first recombinant porcine FVIII treatment for acquired hemophilia A. Bayer has got their injection named Jivi FDA-approved last year for treatment for patients aged 12 or above which will help replace reduced or missing factor VIII and this too will help them acquire a good growth rate during the forecast period. Pfizer has initiated a phase-3 study for safety evaluation of current therapy of factor IX prophylaxis replacement therapy which will help them gain some traction in the market during the forecast period.

FutureWise Key Takeaways:
- Growth prospects
- SWOT analysis
- Key trends
- Key data-points affecting market growth

Objectives of the Study:
- To provide with an exhaustive analysis on the global hemophilia treatment market by region, by type of product, by type of disease, by end user, by
market players
- To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
- To evaluate and forecast micro-markets and the overall market
- To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America
- To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
- Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Table of Contents
1. Introduction
a. Scope and Objective
b. Assumptions and Acronyms
c. Forecast Factors
d. Research Methodology

2. Executive Summary
a. Industry Cluster Analysis
b. Competition Matrix
c. Strategies Recommendations

3. Market Definition
a. Report Scope (Inclusions & Exclusions)
b. Market Segmentation

4. Global Hemophilia Treatment Market Overview
a. Global Hemophilia Treatment Market Revenue (USD Mn)

5. Key Inclusions
a. Porter's Five Force analysis
b. Market Dynamics
c. Industry Trends
d. Regulatory Guidelines
e. Opportunities in Hemophilia Treatment

6. Competition Dynamics
a. Company Share Analysis (2018)
b. Top 10 Product Pricing by Region

7. Global Hemophilia Treatment Market Revenue (USD Mn), 2018-2026 by Therapy Type
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Therapy Type, 2018-2026
i. Replacement Therapy
ii. Management Therapy

8. Global Hemophilia Treatment Market Revenue (USD Mn), 2018-2026 by End User
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
i. Hospital
ii. Clinic
iii. Others

9. Global Hemophilia Treatment Market Revenue (USD Mn), 2018-2026 by Region
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Region,2026
i. North America
ii. Latin America
iii. Europe
iv. Asia Pacific
v. Rest of world

10. North America Hemophilia Treatment Market Revenue (US$ Mn), 2018-2026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
i. US
ii. Canada
e. Market Revenue (USD Mn) Assessment and Forecast by Therapy Type, 2018-2026
i. Replacement Therapy
ii. Management Therapy
f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
i. Hospital
ii. Clinic
iii. Others

11. Latin America Hemophilia Treatment Market Revenue (US$ Mn), 2018-2026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
i. Brazil
ii. Mexico
iii. Argentina
iv. Rest of Latin America
e. Market Revenue (USD Mn) Assessment and Forecast by Therapy Type, 2018-2026
i. Replacement Therapy
ii. Management Therapy
f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
i. Hospital
ii. Clinic
iii. Others

12. Europe America Hemophilia Treatment Market Revenue (US$ Mn), 2018-2026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
i. Germany
ii. France
iii. Spain
iv. UK
v. Russia
vi. Poland
vii. Rest of Europe
e. Market Revenue (USD Mn) Assessment and Forecast by Therapy Type, 2018-2026
i. Replacement Therapy
ii. Management Therapy
f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
i. Hospital
ii. Clinic
iii. Others

13. Asia Pacific America Hemophilia Treatment Market Revenue (US$ Mn), 2018-2026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
i. Emerging Asia
1. China
2. India
3. ASEAN-5
4. Rest of Emerging Asia
ii. Japan
e. Market Revenue (USD Mn) Assessment and Forecast by Therapy Type, 2018-2026
i. Replacement Therapy
ii. Management Therapy
f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
i. Hospital
ii. Clinic
iii. Others

14. Rest of World America Hemophilia Treatment Market Revenue (US$ Mn), 2018-2026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
i. Middle East
ii. South Africa
iii. North Africa
iv. Rest of World
e. Market Revenue (USD Mn) Assessment and Forecast by Therapy Type, 2018-2026
i. Replacement Therapy
ii. Management Therapy
f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
i. Hospital
ii. Clinic
iii. Others

15. Company Profiles
a. Competition Landscape
b. Global Company Share (USD Mn) Overview, 2018
c. Company Profiles
i. Spark Therapeutics
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
ii. Novo Nordisk
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
iii. Pfizer Inc
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
iv. Bayer AG
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
v. CSL Behring
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
vi. Baxter
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
vii. Kedrion SPA
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management

16. Research Sources & Primary Verbatim

Inquire further details about this report at: sales@futurewiseresearch.com

About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.

Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: sales@futurewiseresearch.com
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com